Member Info for Bermudashorts

Blimey - yes. Tend not to check this stock on a day to day basis and just happened to have a look following the RNS.

Yes, most definitely under the radar. SP has been steadily rising since November and the trading statement issued on 17th Jan seems to have given more momentum to the rise. SP has quietly moved almost unnoticed to an all time high.

Yes, - good progress on recruitment to the ovarian cancer trial and interim analysis looks very encouraging - good progress on use on use of the Parsortix system for research and clinical trials and good to see some facts and figures around that - still a fair way to go yet for submission for approval to the FDA. Looks like 2018 at the very earliest for approval.

update:- AUM across the Company had grown to £745m total dividend for 2016 of 1.1094 pence per share (2015: 0.8875) a 25% increase from the prior year. the Board reconfirms the forecast for 2017 of c. £8.5m of Revenue and c. £3.4m of Operating Profit. http://www.investegate.co.uk/frenkel-topping-grp--fen-/rns/trading-update-and-notice-of-results/201701260700091430V/

Thanks Ivy

Thanks for posting

Believe the annual report is likely by the end of the month. As for the SP, Redx has an impressive and broad pipeline and appears to be well structured and well managed. IMO, the issue is the perennial problem with bios - funding. This sort of pipeline doesn't come cheap and from memory R&D costs for 2016 are predicted to come in somewhere around the £12m mark. They plan to take their Porcupine Inhibitor into the clinic in Q1 2017 and the BTK Inhibitor later in the year so presumably those R&D costs are going to increase. In view of the above, I suspect the market is waiting to see how they're going to fund the development of the pipeline. Am looking forward to reading the annual report when hopefully we may find out more. The other thing with bios of course, is that they can turn on a sixpence and a licensing deal could come completely out of the blue.

Positive update this morning. · Unaudited 2016 revenues expected to be approximately £38 million - up 26% from £30.2 million in 2015 · Approximately £42 million of contracts were won in 2016 up 50% from £28 million in 2015 · Exited year with backlog of contracted future work of approximately £70 million http://www.investegate.co.uk/ergomed-plc--ergo-/rns/trading-statement/201701170700072961U/

Several tweets from FTI consulting with photos and sound bites from Andrew Newland's presentation in San Francisco yesterday. https://twitter.com/search?f=tweets&q=parsortix&src=typd

Steady rise continues. Wish the 3 month chart for all stocks in my portfolio looked like this. Stephen Stamp, Chief Finance Officer for Ergomed will be presenting at an Equity Development Investment Forum on 25th Jan in London. More importantly, Andrew Mackie is presenting at the invitation only JP Morgan Healthcare Conference in San Francisco next week.

FDA approval would be a game changer here so let's hope that recruitment to the US breast cancer studies has gone well and that Angle will be in a position to submit positive data to the FDA during the course of 2017. In the very short term, they are off to San Francisco for JP Morgan and will be presenting at Biotech Showcase. Happy New Year to all!

Clinical trial results from 2 of Ergomed's partners are due very soon. The first is phase IIa trial results for Ferrer's insomnia treatment lorediplon and the second is Aeterna Zentaris' Zoptrex for endometrial cancer. Zoptrex is the big one - it's a phase III trial and if the results are positive a new drug application will be filed in H1 2017 (with the benefit of FDA Special Protocol Assessment). Aeterna Zentaris has already signed 4 licensing agreements for Zoptrex and a successful phase III will presumably trigger milestone payments. Ergomed will be entitled to a share of any payments and royalties if the NDA is approved.

captbonio, Have just read your post from 28th Nov - as you can see, the Frenkel Topping board is one of the quieter ones on this site! Have you reached your decision yet or are you still deliberating?

Dave, B cells form part of your immune system - they produce antibodies to fight disease. Blood cancers such as leukaemia and lymphoma can be due to mutations which result in abnormal B cells. They basically go bonkers, become overactive and grow uncontrollably. Bruton’s tyrosine kinase (BTK) is a protein which forms a key part of the B-cell receptor (BCR) pathway - this is the signalling process which triggers the B cell abnormalities. So in simple terms, BTK inhibitors are designed to block or inhibit the pathways and thus the signals that cause the uncontrolled B cell growth. Imbruvica (ibrutinib) is an irreversible BTK inhibitor sold by Abbvie and has been hugely successful but patients become resistant to treatment. Redx's RXC005 is a reversible BTK inhibitor targeting both natural and mutated BTK. The various graphs on the poster demonstrate preclinical results - that RXC005 does bind to the required BTK targets but not other unintended targets, that it does inhibit the BCR signalling, the length of time it stays active in the body, safety etc. The most interesting graphs are on the right hand side where you will see two different doses of RXC005 are compared with ibrutinib in mice. You can see that although all 3 were effective, RXC005 at both doses was more effective than ibrutinib in terms of both tumour volume and regrowth delay.

DaveWin, I'm not sure that they've presented RX004 in the US - other posters may know more. However, they're due to present a poster on the BTK inhibitor RX005 for leukaemia at the American Society of Hematology annual meeting (ASH) in San Diego from 3rd to 6th Dec. So different pre-clinical products for different cancers (pancreatic/leukaemia) but both being presented at highly prestigious scientific conferences either side of the Atlantic.

Redx will be making a poster presentation on its Porcupine inhibitor RX004 at EORTC-NCI-AACR meeting in Munich today. Taken directly from the conclusion of the abstract:- "These data indicate that RXC004 is a potent inhibitor of Wnt pathway driven cancers models. Data from syngeneic mouse models corroborate literature data suggesting that targeting the Wnt pathway may promote immune response against human cancers [3]. RXC004 is currently undergoing IND enabling studies." Good stuff. http://www.investegate.co.uk/redx-pharma-plc--redx-/rns/rxc004-pre-clinical-profile/201611300700114849Q/ http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr

........of of European PharmInvent Services s.r.o. a European pharmacovigilance and regulatory services business. Initial price of £4.1 m and further payments of up to a total of £2.7 m subject to the achievement of EBITDA targets for 2016, 2017 and 2018. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/acquisition-of-pharminvent/201611290700083466Q/

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has signed a new contract worth €2.5m with Sedana Medical AB ("Sedana Medical"). Venn will carry out a randomised, controlled, open label Phase III study to confirm efficacy and safety of sedation with isoflurane in ventilated ICU patients. This trial is confined to patients in Germany and commences immediately. http://www.investegate.co.uk/venn-life-sciences--venn-/rns/contract-win/201611080700095443O/

Ergomed attending Bio Europe over the next couple of days http://www.ebdgroup.com/bioeurope/core/participating-companies.php?_ga=1.231295071.1507294036.1475222496

Good to see Nicolas Guisot, presenting at ASH 2016 - a major conference attracting a great deal of attention. Link to abstract below. "In conclusion, REDX08608 is a potent and selective, reversible BTK inhibitor with efficacy in lymphoma cell lines that offers the potential to target both wild-type BTK and an important emerging resistance mechanism in patients with CLL progression following ibrutinib-treatment. " https://ash.confex.com/ash/2016/webprogram/Paper92759.html http://www.investegate.co.uk/redx-pharma-plc--redx-/rns/reversible-btk-data-at-ash-meeting/201611040700073173O/